Eli Lilly’s mirikizumab scores positive data in Phase II Crohn’s study
Category: #health  By Mateen Dalal  Date: 2019-05-24
  • share
  • Twitter
  • Facebook
  • LinkedIn

Eli Lilly’s mirikizumab scores positive data in Phase II Crohn’s study

The company plans to initiate Phase III trials to assess mirikizumab’s benefit-risk profile to cure Crohn’s disease.

U.S. pharma giant, Eli Lilly and Co. has recently announced positive data from the Serenity Phase II study that evaluated the efficacy and safety of mirikizumab in patients with moderately to severely active Crohn’s disease.

According to the drug maker, patients treated with investigational antibody mirikizumab achieved reductions in clinical and endoscopic measures of disease activity after 12 weeks compared to placebo. Meanwhile, the maintenance phase of this study is currently ongoing.

Reportedly, in the study, patients with moderately- to severely active Crohn’s disease were randomized to receive either placebo or one of three doses of mirikizumab, which, for the record, is a trial-based antibody that targets the p19 subunit of interleukin 23.

The trial’s primary endpoint assessed mirikizumab against placebo on endoscopic response, which was identified as a 50% reduction from baseline in the severity of individual patient’s disease. Meanwhile, secondary endpoints contained clinical remission as measured by PRO (Patient Reported Outcomes) remission, endoscopic remission, and safety.

Speaking on the results, Lotus Mallbris, Vice-President, Immunology Development, Eli Lilly and Co., said that the company, following its last year’s presentation of positive Phase II results for mirikizumab for the treatment of moderate to severe ulcerative colitis, is delighted to return to DDW to display more positive data for mirikizumab in patients with chronic, inflammatory gastrointestinal diseases.

She said that their firm, while continuing to advance the science of gastroenterology, is hopeful that mirikizumab will help to raise the standard and make remission conceivable for patients living with immune-mediated illnesses like Crohn’s disease.

Reliable reports claim that Elli Lilly is planning to initiate Phase III trials to assess mirikizumab’s benefit-risk profile to cure Crohn’s disease. Whereas mirikizumab, which binds to the p19 subunit of interleukin 23, is being studied for the treatment of immune diseases, including ulcerative colitis, psoriasis, and Crohn’s disease.

Source Credit: https://www.drugdevelopment-technology.com/news/lilly-reports-positive-data-from-phase-ii-study-of-mirikizumab/

https://pharmaceutical-business-review.com/news/lillys-mirikizumab-succeeds-in-phase-2-study-in-crohns-disease/

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More

More News By Mateen Dalal

AstraZeneca to present results of Farxiga’s DAPA-CKD trial at ESC 2020
AstraZeneca to present results of Farxiga’s DAPA-CKD trial at ESC 2020
By Mateen Dalal

According to reliable sources, British-Swedish multinational pharmaceutical company AstraZeneca plc will present the much awaited results of the Phase III DAPA-CKD trial of Farxiga in CKD (chronic kidney disease) at ESC Congress 2020. Sources with r...

FDA grants Emergency Use Authorization to Abbott’s COVID-19 antigen
FDA grants Emergency Use Authorization to Abbott’s COVID-19 antigen
By Mateen Dalal

Abbott Laboratories, a U.S.-based medical devices and healthcare firm, has reportedly received the Emergency Use Authorization (EUA) from the U.S. FDA (Food and Drug Administration) for the detecting COVID-19 virus with its portable antigen test Bina...

Hyundai Wia Corp. signs gun parts export contract with BAE Systems
Hyundai Wia Corp. signs gun parts export contract with BAE Systems
By Mateen Dalal

Hyundai Wia Corp., a South Korea-based defense firm, has reportedly signed gun parts export contract with BAE Systems plc of worth USD 100 million via a pre-value accumulation system. As per the agreement, Hyundai Wia will supply over 106 types of gu...